Systemic Lupus Erythematosus Management

Clinical Presentation and Diagnosis

The American College of Rheumatology suggests that constitutional symptoms, including fever, fatigue, and weight loss, are common in systemic lupus erythematosus, although fever requires exclusion of infection before attributing it to lupus activity alone 1, 2
Mucocutaneous manifestations, such as acute cutaneous lupus, subacute cutaneous lupus, and chronic cutaneous lupus, are associated with systemic lupus erythematosus 3
Hematologic abnormalities, including severe anemia, thrombocytopenia, and leucopenia/lymphopenia, correlate with organ involvement and infection risk in systemic lupus erythematosus patients 1

The European League Against Rheumatism recommends hydroxychloroquine at ≤5 mg/kg real body weight for all systemic lupus erythematosus patients unless contraindicated, as it reduces disease activity, prevents flares, and improves survival 4
The American College of Rheumatology suggests that glucocorticoids should be tapered to <7.5 mg/day prednisone equivalent and withdrawn when possible to prevent organ damage, cataracts, glaucoma, osteoporosis, and infection risk 3, 4
Immunosuppressive therapy, such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide, may be used in patients who fail to respond to hydroxychloroquine alone or in combination with glucocorticoids 4, 5

The European League Against Rheumatism recommends mycophenolate mofetil or azathioprine as maintenance therapy for lupus nephritis after achieving initial response with induction therapy 5, 4
For neuropsychiatric lupus, treatment depends on the underlying pathophysiological mechanism, and may include high-dose IV methylprednisolone plus cyclophosphamide or anticoagulation with warfarin 4, 5
For cutaneous lupus, initial approach includes topical glucocorticoids or calcineurin inhibitors, hydroxychloroquine, and photoprotection with sunscreens 2

The American College of Rheumatology suggests that belimumab, anifrolumab, and voclosporin may be used in patients with refractory systemic lupus erythematosus 4
Rituximab may be used off-label for organ-threatening disease refractory to or with intolerance/contraindications to standard immunosuppressive agents 4

The European League Against Rheumatism recommends that pregnancy can increase systemic lupus erythematosus disease activity, and that lupus nephritis and antiphospholipid antibodies increase risk of adverse pregnancy outcomes 5, 2
Safe medications during pregnancy include prednisolone, azathioprine, hydroxychloroquine, and low-dose aspirin 6, 2
Contraindicated medications during pregnancy include mycophenolate mofetil, cyclophosphamide, and methotrexate 6, 2

The American College of Rheumatology suggests that systemic lupus erythematosus patients have a 5-fold increased mortality risk, and that systematic screening and prevention are mandatory 4
Regular disease activity monitoring using validated activity indices, such as BILAG, SLEDAI, or SLE-DAS, is recommended 4, 2
Comorbidity screening, including infections, cardiovascular disease, osteoporosis, and malignancies, is essential 4, 2

Methotrexate is explicitly contraindicated in patients with lupus nephritis, especially during pregnancy, and major international guidelines do not list it as a therapeutic option for renal disease. EULAR/ERA‑EDTA (2019) and the American College of Rheumatology (2012) both exclude methotrexate from lupus nephritis treatment algorithms. 7
The 2019 EULAR/ERA‑EDTA guidelines for lupus nephritis management make no mention of methotrexate for any class of renal involvement (Class III, IV, or V). 8
The 2012 American College of Rheumatology guidelines similarly omit methotrexate from all treatment pathways for active renal lupus. 9
Systematic reviews of the literature conclude that methotrexate has no role in the treatment of lupus nephritis and should not be used for this indication. Evidence from two large rheumatology journals (2020, 2012) supports this recommendation. 8

Mycophenolate mofetil (2–3 g/day) combined with glucocorticoids is a first‑line induction regimen with efficacy comparable to cyclophosphamide for Class III/IV disease. Guideline strength: strong recommendation. 8
Low‑dose intravenous cyclophosphamide (500 mg every two weeks for six doses) plus glucocorticoids is an alternative first‑line option for induction. Guideline strength: strong recommendation. 10
Combination therapy with tacrolimus and mycophenolate mofetil may be considered, particularly in patients presenting with nephrotic‑range proteinuria; however, additional data are required for non‑Asian populations. Guideline strength: conditional recommendation. 8

Mycophenolate mofetil or azathioprine are the preferred agents for maintenance therapy following an adequate induction response. Guideline strength: strong recommendation. 10
Azathioprine is licensed for systemic lupus erythematosus and has evidence indicating superiority over cyclophosphamide for maintenance after induction therapy in lupus nephritis. Evidence level: moderate. 11